Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats

Journal of Cardiovascular Pharmacology

Volumn 31, Issue 5, 1998, Pages 654-660

  Taylor, Kenneth ^a   Patten, Richard D ^a   Smith, John J ^a   Aronovitz, Mark J ^a   Wight, Joseph ^a   Salomon, Robert N ^a   Konstam, Marvin A ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Angiotensin II; Collagen; Hypertrophy; Myocardial infarction; Proliferation; Ventricular remodeling

Indexed keywords

ANGIOTENSIN ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COLLAGEN METABOLISM; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; GROWTH INHIBITION; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL DIVISION; COLLAGEN; ENALAPRIL; LOSARTAN; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANGIOTENSIN;

EID: 0031969613     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199805000-00002     Document Type: Article

References (42)

1. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 1986;74:693-702.
2. Rumberger JA, Behrenbeck T, Breen JR, Reed JE, Gersh BJ. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. J Am Coll Cardiol 1993;21:673-82.
3. Jeremy RW, Allman KC, Bautovitch G, Harris PJ. Patterns of left ventricular dilation during the six months after myocardial infarction. J Am Coll Cardiol 1989;13:304-10.
4. Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. J Am Coll Cardiol 1992;19:1136-44.
5. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51.
6. Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival after myocardial infarction. Circulation 1987;75:IV-93-7.
7. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80-6.
8. St. John Sutton M, Pfeffer MA, et al., for the SAVE investigators. Quantitative two dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effect of captopril. Circulation 1994;89:68-75.
9. Pfeffer MA, Braunwald E, Moyé LA, et al. for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 1992;327:669-77.
10. Konstam MA, Rousseau MF, Kronenberg MW, et al., for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dysfunction in patients with heart failure. Circulation 1992;86:431-8.
11. Konstam MA, Kronenberg MW, Rousseau MF, et al., for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor, enalapril, on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-83.
12. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
13. Brilla CG, Reans GP, Maisch B, Weber KT. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix. Eur Heart J 1993;14:57-61.
14. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-52.
15. Katz AM. Angiotensin II: Hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990;22:739-47.
16. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993;87:1816-28.
17. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-8.
18. van Krimpen C, Smits JFM, Cleutjens JPM, et al. DNA synthesis in the non-infarcted cardiac interstitium after left coronary artery ligation in the rat: effects of captopril. J Mol Cell Cardiol 1991a;23: 1245-53.
19. 1-adrenoreceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-46.
20. Kanda T, Araki T, Nakano M, Imai S, Suzuki T, Murata K, Kobayashi I. Chronic effects of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther 1995;273:955-8.
21. Urata H, Healy B, Stewart RW, Bumpus FM., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
22. Pfeffer MA, Pfeffer JM, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 1979;44:503-12.
23. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Circ Res 1981;49:618-26.
24. Rasband W. NIH Image Analysis Program, U.S. National Institutes of Health. Available from the internet by anonymous ftp from Zippy.nimh.nih.gov or on floppy disk from NTIS, 5285 Port Royal Road, Springfield, VA 22161, Part No. PB93-504868, 1995.
25. Yu CC-W, Filipe MI. Update on proliferation-associated antibodies applicable to formalin fixed paraffin embedded tissue and their clinical applications. Histochem J 1993;25:843-53.
26. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757-65.
27. Booz GW, Baker KM. Molecular signaling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995;30:537-43.
28. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptidcs and angiotensin converting enzyme. J Cardiovasc Pharmacol 1995;26:233-40.
29. Schieffer B, Wirger A, Meybrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
30. Crabos M, Roth M, Hahn AWA, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. J Clin Invest 1994;93:2372-8.
31. Villarreal FJ, Kim NN, Ungab G, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993;88:2849-61.
32. 1 receptor subtype. Circ Res 1993;73:413-23.
33. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993;72:1245-54.
34. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
35. Brink M, Erne P, deGasparo M, et al. Localization of the angiotensin II receptor subtypes in the human atrium. J Mol Cell Cardiol 1996;28:1789-99.
36. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515-20.
37. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-8.
38. Linz W, Wiemer G, Schölkens BA. Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 1993;22:S1-8.
39. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8.
40. Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-10.
41. Garg UC, Hassis A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
42. Yamazaki T, Komuro I, Kudoh S, et al. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res 1995;77:258-65.